Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma

Frontiers in Pediatrics

article

Francesca Santamaria¹  Carla Ziello¹  Paola Lorello¹  Cristina Bouchè¹  Melissa Borrelli¹ 

[1] Department of Translational Medical Sciences, University of Naples Federico II

关键词: asthma;    children;    adolescents;    preschool children;    long-acting anticholinergics;    tiotropium bromide;   

DOI  :  10.3389/fped.2022.896865

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs.

【 授权许可】

CC BY